Imatinib

Generic Name: Imatinib

Brand Names: Gleevec, Glivec, Imatinib Teva, Imatinib Accord

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₁N_₇O

CAS Number: 152459-95-5

Unique Ingredient Identifier: BKJ8M8G5HI

Background: Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and ...

Indication: Imatinib is indicated for the treatment of adult and pediatric chronic myeloid leukemia with Philadelphia chromosome mutation (Ph+) in blast crisis, accelerated phase, or chronic phase after IFN-alpha therapy failure.Additionally, imatinib is also indicated to treat adult and pediatric Ph+ acute lymphoblastic leukemia, adult myelodysplastic/myeloproliferativ...

Associated Conditions: Accelerated Phase Chronic Myelogenous Leukemia (CML), Aggressive Systemic Mastocytosis, Chordomas, Chronic Eosinophilic Leukemia, FIP1L1-PDGFRα fusion kinase status unknown Chronic eosinophilic leukemia, FIP1L1-PDGFRα fusion kinase status unknown Hypereosinophilic syndrome, Gastrointestinal Stromal Tumor (GIST), Hypereosinophilic Syndrome (HES), Metastatic Gastrointestinal Stromal Tumor (GIST), Metastatic Melanoma, Myelodysplastic Syndrome, Myeloproliferative Disorders (MPD), Refractory Acute Lymphoblastic Leukemia (ALL), Blast phase Chronic myeloid leukemia, CKit mutational status unknown Aggressive systemic mastocytosis, Metastatic Dermatofibrosarcoma protuberans, Newly diagnosed Acute Lymphoblastic Leukaemia, Newly diagnosed, chronic phase Chronic myeloid leukemia, Recurrent Dermatofibrosarcoma protuberans, Refractory, chronic phase Chronic myeloid leukemia, Unresectable Gastrointestinal stromal tumor

Associated Therapies: -

Clinical Trials

Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS

First Posted Date: 2024-11-18

Last Posted Date: 2024-11-18

Lead Sponsor: Peking University Shenzhen Hospital

Target Recruit Count: 200

Registration Number: NCT06692491

Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease

Phase 3

Recruiting

Conditions: Graft-versus-host Disease

Interventions: Drug: Rovadicitinib
Drug: Imatinib
Drug: Methotrexate
Drug: Mycophenolate mofetil
Drug: Rituximab

First Posted Date: 2024-11-12

Last Posted Date: 2024-11-26

Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Target Recruit Count: 182

Registration Number: NCT06682169

Locations: 🇨🇳
The First Affiliated Hospital of USTC Anhui Provincial Hospital, Hefei, Anhui, China

Correlation Between Imatinib Trough Concentration and Efficacy in Advanced GIST Patients with Different Genotypes

Completed

Conditions: Gastrointestinal Stromal Tumor, Malignant

First Posted Date: 2024-10-07

Last Posted Date: 2024-10-07

Lead Sponsor: First Affiliated Hospital, Sun Yat-Sen University

Target Recruit Count: 168

Registration Number: NCT06628739

Locations: 🇨🇳
The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China

Investigation of Novel and Established Therapies in a Human Intravenous Lipopolysaccharide Model of Sepsis

Phase 1

Not yet recruiting

Conditions: Sepsis
Fluid Overload
Endothelial Dysfunction
Microcirculation

Interventions: Drug: Imatinib
Drug: Compound sodium lactate solution

First Posted Date: 2024-10-04

Last Posted Date: 2024-10-04

Lead Sponsor: Belfast Health and Social Care Trust

Target Recruit Count: 65

Registration Number: NCT06626984

Ma-Spore ALL 2020 Study

Phase 2

Recruiting

Conditions: B Lymphoblastic Leukemia

Interventions: Drug: Prednisolone
Drug: Dexamethasone
Drug: Vincristine
Drug: Methotrexate
Drug: L-Asparaginase
Drug: Pegylated asparaginase
Drug: Erwinase
Drug: Dasatinib
Drug: Cytarabine
Drug: Imatinib
Drug: Cyclophosphamide
Drug: Mercaptopurine
Drug: Rituximab
Drug: Thioguanine
Drug: Doxorubicin
Drug: Fludarabine

First Posted Date: 2024-03-28

Last Posted Date: 2024-03-28

Lead Sponsor: National University Hospital, Singapore

Target Recruit Count: 500

Registration Number: NCT06336395

Locations: 🇲🇾
University Malaya Medical Centre, Kuala Lumpur, Malaysia
🇲🇾
Subang Jaya Medical Centre, Kuala Lumpur, Malaysia
🇸🇬
KK Women's and Children's Hospital, Singapore, Singapore